Forte Biosciences, Inc.: TYBOURNE CAPITAL MANAGEMENT (HK) LTD amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Tybourne Capital Management (HK) Ltd amended its Schedule 13G filing on Forte Biosciences, Inc., updating its passive stake disclosure with the SEC under accession number 0000929638-26-004231. The amendment signals a change in the institutional investor's reported position, though the filing did not specify the size or direction of the adjustment in the headline. Schedule 13G amendments are typically watched for shifts in ownership by large passive holders, which can affect float and governance dynamics at small-cap biotech firms like Forte. Investors will look to the full filing for the updated share count and percentage owned, and to any subsequent 13F or Form 4 disclosures for confirmation of Tybourne's current exposure.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
TYBOURNE CAPITAL MANAGEMENT (HK) LTD, Forte Biosciences, Inc.